{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Progyny, Inc.
Progyny, Inc. Hits Day High with 24.21% Surge in Stock Price
Progyny, Inc. has shown remarkable stock performance, significantly outperforming the S&P 500 over various timeframes. The company reports strong financial fundamentals, including a high Return on Equity and impressive growth rates in net sales and operating profit, alongside a low debt-to-equity ratio and full institutional ownership.
Progyny, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Progyny, Inc. has recently adjusted its valuation, with its stock price rising to $22.37. Over the past year, the company has achieved a 35.33% return, outperforming the S&P 500. Key metrics include a P/E ratio of 35 and a return on capital employed of 34.17%, indicating strong financial performance.
Is Progyny, Inc. overvalued or undervalued?
As of November 7, 2025, Progyny, Inc. is considered overvalued due to high valuation ratios compared to peers, despite a strong short-term stock return, as its long-term performance has significantly lagged behind the S&P 500.
Is Progyny, Inc. overvalued or undervalued?
As of October 17, 2025, Progyny, Inc. is considered overvalued with a P/E ratio of 35 and has underperformed the S&P 500, showing a 3-year return of -50.09% compared to the index's 81.19%.
Progyny, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Progyny, Inc. has recently adjusted its valuation metrics, reporting a P/E ratio of 35 and a price-to-book value of 3.98. The company exhibits strong returns, with a ROCE of 34.17% and an ROE of 11.24%. Despite recent stock price declines, it has achieved a year-to-date return of 12.12%.
Is Progyny, Inc. overvalued or undervalued?
As of October 17, 2025, Progyny, Inc. is considered overvalued with a P/E ratio of 35 and significant underperformance compared to the S&P 500, leading to a shift in its valuation grade from attractive to expensive.
Is Progyny, Inc. overvalued or undervalued?
As of October 17, 2025, Progyny, Inc. is considered overvalued with a P/E ratio of 35 and has underperformed the S&P 500 significantly over the past three and five years, suggesting its current market valuation is not justified compared to peers.
Progyny, Inc. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators
Progyny, Inc. has recently seen a revision in its evaluation, with its stock price at $20.19. The company has experienced significant volatility over the past year, with mixed technical indicators reflecting varying trends. Despite recent underperformance compared to the S&P 500, Progyny has shown resilience with positive year-to-date and one-year returns.
Is Progyny, Inc. technically bullish or bearish?
As of October 3, 2025, Progyny, Inc. shows a mildly bearish trend, with bearish signals from the weekly MACD and Bollinger Bands, despite a mildly bullish daily moving average, and has underperformed the S&P 500 recently.
Is Progyny, Inc. technically bullish or bearish?
As of October 3, 2025, Progyny, Inc. has shifted to a mildly bearish trend, with weekly indicators signaling bearishness despite mildly bullish daily moving averages, and it has underperformed the S&P 500 in the short term while outperforming it year-to-date and over the past year.
Is Progyny, Inc. technically bullish or bearish?
As of October 3, 2025, Progyny, Inc. has shifted to a mildly bearish trend due to negative weekly indicators, despite outperforming the S&P 500 year-to-date and over the past year.
Is Progyny, Inc. technically bullish or bearish?
As of September 12, 2025, Progyny, Inc. shows a mildly bullish trend supported by daily indicators, despite mixed signals from weekly metrics and underperformance compared to the S&P 500, with a year-to-date return of 30.55% versus the index's 12.22%.
Is Progyny, Inc. overvalued or undervalued?
As of February 27, 2025, Progyny, Inc. is considered overvalued with a high P/E ratio of 35 and poor stock performance, showing a 1-year return of -7.86% compared to the S&P 500's 17.14% gain.
Progyny, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Progyny, Inc. has recently seen a stock price adjustment, currently at $22.13, following a year of notable volatility with a high of $26.76 and a low of $13.39. Technical indicators present mixed signals, while the company's year-to-date performance shows strong returns compared to the S&P 500, despite longer-term challenges.
Is Progyny, Inc. overvalued or undervalued?
As of June 13, 2025, Progyny, Inc. is considered overvalued with a very expensive valuation grade, reflected in its high P/E ratio of 35 and EV to EBITDA of 20.94, especially compared to peers like Grand Canyon Education and MAXIMUS, and it has underperformed with a 1-year return of -19.61% versus the S&P 500's 10.26% gain.
Is Progyny, Inc. technically bullish or bearish?
As of May 9, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators are mildly bearish and Bollinger Bands show bearish signals, indicating potential volatility ahead.
Who are in the management team of Progyny, Inc.?
As of March 2022, Progyny, Inc.'s management team includes Dr. Beth Seidenberg (Independent Chairman), Mr. David Schlanger (CEO), and Directors Malissia Clinton, Roger Holstein, Frederick Cohen, Kevin Gordon, and Jeffrey Park. They are responsible for guiding the company's strategy and operations.
What does Progyny, Inc. do?
Progyny, Inc. is a fertility benefits management company in the U.S. that provides fertility and family building solutions, with a recent net sales of $324 million and a market cap of approximately $1.85 billion.
How big is Progyny, Inc.?
As of Jun 18, Progyny, Inc. has a market capitalization of $1.85 billion, with net sales of $1.21 billion and a net profit of $52.49 million for the latest four quarters. The balance sheet as of December 2024 shows shareholder's funds of $422.06 million and total assets of $612.15 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
